Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. develops telitacicept for autoimmune diseases, with company updates centered on clinical development, financing, governance and employee equity compensation. Telitacicept is described by the company as a dual BAFF/APRIL inhibitor and novel dual-target fusion protein for autoantibody-driven conditions, with global Phase 3 programs in generalized myasthenia gravis and primary Sjögren’s disease.
Recurring news includes clinical-trial starts and data discussions, financial results and balance-sheet updates, private-placement financing, board appointments, investor-conference presentations and Nasdaq inducement grants under the Vor Biopharma Inc. 2023 Inducement Plan. Company announcements also reflect telitacicept regulatory status in China and global development across major autoimmune indications.
Vor Bio (VOR) has completed enrollment in UPSTREAM MG, its global Phase 3 registrational trial of telitacicept in generalized myasthenia gravis (gMG), with topline data from the 24-week primary endpoint expected in the first half of 2027.
The company also plans to start UPSTREAM oMG, a global Phase 3 registrational trial of telitacicept in ocular myasthenia gravis (oMG), with first patient dosing anticipated in the first half of 2027. This represents a planned registrational expansion of Vor Bio’s MG program, aimed at potential future label expansion across the myasthenia gravis spectrum and building on broader telitacicept experience, including an ongoing Phase 3 oMG trial in China conducted by RemeGen.
Vor Bio (VOR) granted inducement equity awards to six newly hired employees on September 1, 2026 under its 2023 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The awards consist of stock options to purchase an aggregate of 83,600 shares and RSUs covering 17,900 shares of common stock. The options have a ten-year term and an exercise price of $22.64, equal to the closing price on the grant date. Both options and RSUs vest over four years, with 25% vesting after 12 months and the remainder vesting over the following 36 months, subject to continued employment and the applicable award agreements.
Vor Bio (Nasdaq: VOR) announced management participation in several September 2026 investor events, including the Wells Fargo Healthcare Conference on September 8 (8:00AM ET), Citi’s Biopharma Back to School Conference on September 9 (11:20AM ET), Morgan Stanley’s Global Healthcare Conference on September 14, Baird’s Global Healthcare Conference on September 15 (9:05AM ET), and Stifel’s Virtual Immunology and Inflammation Forum on September 23 (11:30AM ET). A live webcast and 30-day replay of presentations will be available on Vor Bio’s investor relations website.
Vor Bio (Nasdaq: VOR) reported second quarter 2026 results and a corporate update, highlighting continued progress with telitacicept. Enrollment is ongoing and described as on track in the global Phase 3 UPSTREAM MG trial in generalized myasthenia gravis, with topline data expected in 1H 2027, and in the Phase 3 UPSTREAM SjD trial in primary Sjögren’s disease.
According to the company, China’s NMPA approved telitacicept for adult Sjögren’s disease and IgA nephropathy, and Phase 3 TELIGAN IgAN results were published in The New England Journal of Medicine. Pro-forma cash and investments of $514.5 million are projected to fund operations into early 2029. Q2 2026 R&D expenses were $25.9 million and G&A $21.9 million, with a net loss of $62.8 million, substantially lower than the prior-year period due mainly to changes in warrant fair value.
Vor Bio (Nasdaq: VOR) reported that on August 1, 2026, its Board Compensation Committee granted stock options for an aggregate 32,550 shares and RSUs for 6,900 shares of common stock to five newly hired employees. The awards were approved as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and issued pursuant to the 2023 Inducement Plan.
The stock options have a ten-year term and an exercise price of $21.15 per share, equal to the closing price on the grant date. Options and RSUs each vest over four years, starting with 25% after 12 months and the remainder vesting monthly (options) or quarterly (RSUs), subject to continued employment.
Vor Bio (Nasdaq: VOR) appointed David Zaccardelli, Pharm.D., to its Board of Directors, adding more than 20 years of biopharma leadership as the company advances telitacicept through global Phase 3 development in autoimmune diseases.
Zaccardelli previously led Verona Pharma through FDA approval, commercial launch of Ohtuvayre, and a $10 billion acquisition by Merck, and earlier led Dova Pharmaceuticals through a sale worth up to $915 million. In connection with this appointment, Andrew Levin, M.D., Ph.D., has stepped down from the Board.
Vor Bio (Nasdaq: VOR) granted inducement equity awards to 7 newly hired employees under its 2023 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Awards include stock options for 71,200 shares at $18.39 per share and RSUs for 15,150 shares, each vesting over four years.
Vor Bio (Nasdaq: VOR)/b) and partner RemeGen announced that China’s NMPA has approved for adult patients with Sjögren’s disease (SjD), the first and only approved SjD therapy in China.
The decision is based on a Phase 3 trial showing statistically significant ESSDAI and clinically meaningful ESSPRI improvements, with a favorable safety profile. This is the fifth approved indication for telitacicept.
Vor Bio (Nasdaq: VOR) and collaborator RemeGen announced that China’s NMPA has conditionally approved telitacicept for adult IgA nephropathy, the first BAFF/APRIL-targeting therapy for IgAN and the drug’s fourth approved indication.
Approval is based on Phase 2 and Phase 3 TELIGAN data showing a 59% UPCR reduction and favorable safety.
Vor Bio (Nasdaq: VOR) granted equity awards on June 1, 2026 to 10 newly hired employees under its 2023 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards include stock options for 61,050 shares at $14.57 and RSUs for 12,900 shares, both vesting over four years.